Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

NCT01625741 is registered in ClinicalTrials.gov with Cliniques universitaires Saint-Luc- Université Catholique de Louvain as lead sponsor.

NCT NCT01625741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01625741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy
Lead sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
May 31, 2015
Enrollment
6 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia